Q2 26 EPS GAAP
$-0.80
BEAT +10.92%
Est. $-0.90
Q2 26 Revenue
$7.7M
MISS 40.99%
Est. $13.0M
vs S&P Since Q2 26
+8.8%
BEATING MARKET
NTLA +9.4% vs S&P +0.6%
Market Reaction
Did NTLA Beat Earnings? Q2 2026 Results
Intellia Therapeutics delivered a mixed second quarter for 2026, missing on both the top and bottom lines even as a landmark clinical readout underscored the promise of its gene editing platform. The company posted a GAAP net loss of $0.80 per share,… Read more Intellia Therapeutics delivered a mixed second quarter for 2026, missing on both the top and bottom lines even as a landmark clinical readout underscored the promise of its gene editing platform. The company posted a GAAP net loss of $0.80 per share, falling short of the $0.78 consensus by 1.95%, snapping a streak of six consecutive quarterly EPS beats. Collaboration revenue tumbled 46.2% year over year to $7.66 million, coming in well below the $12.98 million analysts had expected, as reduced contributions from Regeneron on the nex-z program weighed heavily on the top line. The headline story, however, was the Phase 3 HAELO trial for lonvoguran ziclumeran in hereditary angioedema, which demonstrated an 87% reduction in attacks versus placebo and was published in the New England Journal of Medicine. G&A expenses climbed to $37.82 million from $27.21 million a year ago, reflecting aggressive commercial buildout ahead of a planned U.S. Launch in the first half of 2027, contingent on BLA acceptance expected later this year. Intellia ended the quarter with $628.35 million in cash, providing runway into at least 2028.
Key Takeaways
- • Positive Phase 3 HAELO data for lonvo-z driving regulatory and commercial momentum
- • R&D expense reduction driven by lower external costs on lead development programs and reduced stock-based compensation
- • G&A expense increase driven by commercial infrastructure buildout for anticipated lonvo-z launch
- • Collaboration revenue decline primarily due to reduced revenue from Regeneron
NTLA Forward Guidance & Outlook
Intellia expects FDA acceptance of its BLA submission for lonvo-z in the second half of 2026, with a planned U.S. commercial launch in the first half of 2027. The company expects to complete MAGNITUDE-2 enrollment for nex-z in ATTRv-PN in the second half of 2026. Cash, cash equivalents and marketable securities of approximately $628 million are expected to fund operations at least into 2028 and well beyond lonvo-z's anticipated U.S. commercial launch, excluding potential commercial revenues from lonvo-z.
NTLA YoY Financials
Q2 2026 vs Q2 2025, source: SEC Filings
NTLA Revenue by Segment
With YoY comparisons, source: SEC Filings
“The second quarter was a momentous period for Intellia highlighted by the positive Phase 3 HAELO clinical trial results we reported for lonvo-z in hereditary angioedema. These data serve as strong validation for in vivo gene editing and lonvo-z's potential to transform the treatment paradigm for patients who are burdened by this disease.”
— John Leonard, Q2 2026 Earnings Press Release
NTLA Earnings Trends
NTLA vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
NTLA EPS Trend
Earnings per share: estimate vs actual
NTLA Revenue Trend
Quarterly revenue: estimate vs actual
NTLA Quarterly Results
7 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q2 26 BEAT | $-0.90 | $-0.80 | +10.92% | $7.7M | -40.99% |
| Q1 26 BEAT | $-0.90 | $-0.81 | +9.81% | $15.0M | +8.99% |
| Q4 25 BEAT FY | $-0.96 | $-0.83 | +13.71% | $23.0M | +89.08% |
| FY Full Year | $-4.00 | $-3.81 | +4.75% | $67.7M | +18.53% |
| Q3 25 BEAT | $-0.98 | $-0.92 | +6.49% | $13.8M | -2.41% |
| Q2 25 BEAT | $-1.01 | $-0.98 | +2.51% | $14.2M | +17.12% |
| Q1 25 BEAT | $-1.27 | $-1.10 | +13.46% | $16.6M | +38.72% |
| Q4 24 BEAT FY | $-1.32 | $-1.27 | +3.52% | $12.9M | +58.94% |
| FY Full Year | — | $-5.25 | — | $57.9M | — |